JP2022534837A5 - - Google Patents

Info

Publication number
JP2022534837A5
JP2022534837A5 JP2021558535A JP2021558535A JP2022534837A5 JP 2022534837 A5 JP2022534837 A5 JP 2022534837A5 JP 2021558535 A JP2021558535 A JP 2021558535A JP 2021558535 A JP2021558535 A JP 2021558535A JP 2022534837 A5 JP2022534837 A5 JP 2022534837A5
Authority
JP
Japan
Prior art keywords
cancer
chimeric protein
cells
disease
protein complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021558535A
Other languages
English (en)
Japanese (ja)
Other versions
JP7689079B2 (ja
JP2022534837A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025411 external-priority patent/WO2020198654A1/en
Publication of JP2022534837A publication Critical patent/JP2022534837A/ja
Publication of JP2022534837A5 publication Critical patent/JP2022534837A5/ja
Priority to JP2025019797A priority Critical patent/JP2025072580A/ja
Application granted granted Critical
Publication of JP7689079B2 publication Critical patent/JP7689079B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021558535A 2019-03-28 2020-03-27 治療用インターフェロンアルファ1タンパク質 Active JP7689079B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025019797A JP2025072580A (ja) 2019-03-28 2025-02-10 治療用インターフェロンアルファ1タンパク質

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962825569P 2019-03-28 2019-03-28
US62/825,569 2019-03-28
US201962906431P 2019-09-26 2019-09-26
US62/906,431 2019-09-26
PCT/US2020/025411 WO2020198654A1 (en) 2019-03-28 2020-03-27 Therapeutic interferon alpha 1 proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025019797A Division JP2025072580A (ja) 2019-03-28 2025-02-10 治療用インターフェロンアルファ1タンパク質

Publications (3)

Publication Number Publication Date
JP2022534837A JP2022534837A (ja) 2022-08-04
JP2022534837A5 true JP2022534837A5 (enExample) 2023-04-03
JP7689079B2 JP7689079B2 (ja) 2025-06-05

Family

ID=72603959

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558535A Active JP7689079B2 (ja) 2019-03-28 2020-03-27 治療用インターフェロンアルファ1タンパク質
JP2025019797A Pending JP2025072580A (ja) 2019-03-28 2025-02-10 治療用インターフェロンアルファ1タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025019797A Pending JP2025072580A (ja) 2019-03-28 2025-02-10 治療用インターフェロンアルファ1タンパク質

Country Status (6)

Country Link
US (2) US11440943B2 (enExample)
EP (1) EP3946410A4 (enExample)
JP (2) JP7689079B2 (enExample)
CN (1) CN113767115B (enExample)
CA (1) CA3133643A1 (enExample)
WO (1) WO2020198654A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3455245A2 (en) * 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
JP7773372B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ,インコーポレイテッド 線維芽細胞活性化タンパク質結合物質およびその使用
US11440943B2 (en) * 2019-03-28 2022-09-13 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins
WO2021062184A1 (en) * 2019-09-26 2021-04-01 Orionis Biosciences, Inc. Pd-l1 targeted chimeric proteins and uses thereof
US20230242655A1 (en) 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
CN113717942B (zh) * 2020-05-26 2024-04-30 华东师范大学 一种联合嵌合抗原受体和i型干扰素的免疫治疗方法及其应用
WO2022140797A1 (en) * 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
CN118103407A (zh) * 2021-08-12 2024-05-28 上海才致药成生物科技有限公司 一种双特异性重组蛋白及其用途
EP4412636A4 (en) * 2022-06-01 2025-09-17 Remd Biotherapeutics Inc NOVEL INTERFERON VARIANTS AND BIFUNCTIONAL FUSION MOLECULES THEREOF
EP4543488A2 (en) * 2022-08-25 2025-04-30 Bright Biologics LLC Multispecific antibodies and uses thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE69007975T2 (de) 1989-08-22 1994-07-21 Immunex Corp Fusionsprotein bestehend aus gm-csf und il-3.
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
EP1739090A3 (en) 1998-10-16 2009-04-08 Biogen Idec MA Inc. Interferon-beta fusion proteins and uses
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US20110020273A1 (en) 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
WO2006004959A2 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
WO2006120580A2 (en) 2005-05-04 2006-11-16 Nautilus Biotech Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
US20080038224A1 (en) 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
US7947265B2 (en) 2006-08-02 2011-05-24 Mcgill University Fusion proteins and methods for modulation of immune response
AU2007331672A1 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
WO2009003145A1 (en) 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
CN101868246A (zh) * 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
CN101525381B (zh) 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
WO2010030671A1 (en) 2008-09-09 2010-03-18 University Of Medicine And Dentistry Of New Jersey Type i interferon antagonists
US8334101B2 (en) 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
WO2010066740A1 (en) 2008-12-08 2010-06-17 Complix Nv Single-chain antiparallel coiled coil proteins
WO2011017160A1 (en) * 2009-07-28 2011-02-10 Pestka Biomedical Laboratories, Inc. Mutant human interferon proteins and genes
JP5764127B2 (ja) 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
JP2013504539A (ja) 2009-09-10 2013-02-07 サイトス バイオテクノロジー アーゲー 糖尿病治療におけるインターロイキン1βムテイン・コンジュゲートの使用
EP2343081A1 (en) 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Interferon analogs
US9534056B2 (en) 2011-06-06 2017-01-03 Immungene Inc Engineered TAA antibody-TNFSF member ligand fusion molecules
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
ES2694180T3 (es) 2012-01-20 2018-12-18 Vib Vzw Citocinas de haz alfa-helicoidal mutantes dirigidas
PT2822575T (pt) 2012-03-03 2020-07-02 Immungene Inc Moléculas de fusão anticorpos-mutante de interferão modificadas
EP3666795A1 (en) 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
CN103319608B (zh) 2013-07-01 2014-08-27 江苏众红生物工程创药研究院有限公司 猪IFNɑ1-Fc融合蛋白及其编码基因和表达方法
KR102322510B1 (ko) 2013-07-18 2021-11-08 브이아이비 브이지더블유 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인
JP6595988B2 (ja) 2013-07-19 2019-10-23 ヴィブ ブイゼットダブリュー ターゲットされる修飾tnfファミリーメンバー
BR112016001128A2 (pt) 2013-07-19 2018-01-23 Vib Vzw membros da família il-1 modificados direcionados
SG10202010429YA (en) 2013-07-19 2020-11-27 Vib Vzw Targeting of cytokine antagonists
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
US11186641B2 (en) 2016-03-17 2021-11-30 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
EP3664829A4 (en) 2017-08-09 2021-05-05 Orionis Biosciences, Inc. LIAISON OFFICERS AT PD-1 AND PD-L1
AU2018313810B2 (en) 2017-08-09 2025-05-15 Orionis Biosciences BV Clec9A binding agents and use thereof
CN111511763B (zh) 2017-08-09 2024-05-31 奥里尼斯生物科学有限公司 Cd8结合剂
EP3743448A4 (en) 2018-01-26 2021-11-03 Orionis Biosciences, Inc. XCR1 BINDING AGENTS AND USES THEREOF
KR102877915B1 (ko) 2018-02-05 2025-10-29 오리오니스 바이오사이언시즈 인코포레이티드 섬유아세포 결합제 및 이의 용도
KR20210005872A (ko) 2018-03-28 2021-01-15 오리오니스 바이오사이언시즈 인코포레이티드 이작용성 단백질 및 이의 작제물
WO2020033646A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
CA3125527A1 (en) 2018-12-20 2020-06-25 Orionis Biosciences, Inc. Particle based small molecule-protein complex trap
US20220177550A1 (en) * 2019-03-28 2022-06-09 Orionis Biosciences, Inc. Chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3)
US11440943B2 (en) * 2019-03-28 2022-09-13 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins

Similar Documents

Publication Publication Date Title
JP2022534837A5 (enExample)
Strohl Current progress in innovative engineered antibodies
JP2024522949A5 (enExample)
JP5745854B2 (ja) Tl1aに対するヒト化抗体
JP2020506727A5 (enExample)
JP2020501531A5 (enExample)
TW202003583A (zh) 抗muc1抗體
JP2020531043A5 (enExample)
RU2018139339A (ru) Новые биспецифические полипептиды против cd137
JP2021513361A5 (enExample)
RS62151B1 (sr) Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu
JP2019523630A5 (enExample)
Han et al. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy
KR20160127131A (ko) 항 인간 인터루킨-1 수용체 부속 단백질 (il1 rap) 항체 및 이의 용도
RU2020142965A (ru) Иммуноглобулин с тандемным расположением fab-фрагментов и его применение
US12312409B2 (en) Bispecific CD137-binding antibodies for T-cell activation
JP2022512891A5 (enExample)
JP2022550345A5 (enExample)
IL301472A (en) Specificity-enhanced bispecific antibody (SEBA)
JP2025148434A (ja) PD-1とTGF-βに対する二機能性タンパク質
JP7812988B2 (ja) Lewis Yに対するヒト化抗体
JP2022530742A5 (enExample)
JP2019512210A5 (enExample)
CN115894702A (zh) 一种b7h3/pdl1双特异性抗体及其药物组合物及应用
EP4667491A1 (en) Anti-cntn4 antibody and uses thereof